Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction
NCT06161818Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2025
- Primary completion
- Sep 2029
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, folinic acid, oxaliplatin, docetaxel, carboplatin in esophageal adenocarcinoma (EAC), sponsored by Erasmus MC. Started Sep 2025; status: recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatindocetaxelcarboplatin
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT06161818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06161818.